Plain-English translation of NCT04671667 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , an immunotherapy drug that helps your immune system fight cancer, works as well as or better than the standard treatment of chemotherapy combined with radiation therapy after surgery for recurrent head and neck cancer. You would be randomly assigned to receive either the medication alone or the standard chemotherapy and radiation combination. The trial will measure which approach helps patients live longer and keeps cancer from coming back.
Recurrent head and neck cancer is very difficult to treat, especially when it comes back in an area that was previously treated with radiation. Doctors want to know if this newer immunotherapy medication could be a gentler and more effective option than giving chemotherapy and radiation again, which can cause significant side effects.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two treatment groups. One group receives by intravenous infusion every 6 weeks for 9 cycles (about 9 months), while the other group receives chemotherapy drugs by infusion once weekly for 6 weeks plus daily radiation therapy for 6 weeks. Throughout the trial and for 5 years afterward, you will have regular CT or MRI scans to monitor how well the treatment is working. You will have a follow-up visit 30 days after treatment ends, and then every 6 months for up to 5 years.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States